Oxalessigsure
OXALACETIC ACID · OXALOACETIC ACID · 2-OXOSUCCINIC ACID · OAA · OXOBUTANEDIOIC ACID · oxalacetic · NSC 77688 · NSC 284205
Identifikatoren & physikalische Daten
| CAS No. | 328-42-7 |
|---|---|
| Summenformel | C4H4O5 |
| Durchschnittliche Molmasse | 132,07 g/mol |
| Monoisotopische Masse | 132,00587323 g/mol |
| SMILES | O=C(O)CC(=O)C(=O)O |
| InChIKey | KHPXUQMNIQBQEV-UHFFFAOYSA-N |
| PubChem CID | 970 |
| ChEMBL | CHEMBL1794791 |
| ChEBI | CHEBI:30744 |
| EC No. | 206-329-8 |
| DTXSID | DTXSID8021646 |
| Lokaler Name | Oxalessigsure |
Chemische & physikalische Eigenschaften
| XLogP | -0,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 91,7 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 5 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 9 |
| Formalladung | 0 |
| Komplexität | 158 |
| Stoffklassen | Other Classes -> Organic Acids |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
| Lipide | Fatty Acyls [FA] -> Fatty Acids and Conjugates [FA01] -> Dicarboxylic acids [FA0117] |
| Löslichkeit | 134 mg/mLH2O: 100 mg/mLsoluble |
| Schmelzpunkt | 161 °C161 °C (dec.)(lit.) |
| Physical Description | Off-white powder[Alfa Aesar MSDS]Solid |
| Collision Cross Section | 139.45 Ų [M+H]+ [CCS Type: DTMethod: stepped-field] |
| Siedepunkt | 163.94°C (rough estimate) |
| Dichte | 1.3067 (rough estimate) |
| Dampfdruck | 0.003Pa at 20℃ |
| Brechungsindex | 1.4000 (estimate) |
| Flammpunkt | 88°C |
| Lagerbedingungen | -20°C |
| Aggregatzustand | powder |
| pKa (Säurekonstante) | 2.22(at 25℃) |
| Farbe | White to off-white |
| pH | 3.05(1 mM solution)2.29(10 mM solution)1.68(100 mM solution) |
| Biologische Quelle | synthetic (organic) |
| Merck | 14,6909 |
| BRN | 1705475 |
| Stabilität | Stable. Incompatible with strong oxidizing agents. Keep refrigerated. |
| InChI | 1S/C4H4O5/c5-2(4(8)9)1-3(6)7/h1H2,(H,6,7)(H,8,9) |
| InChIKey | KHPXUQMNIQBQEV-UHFFFAOYSA-N |
| SMILES | OC(=O)CC(=O)C(O)=O |
| LogP (Verteilungskoeffizient) | -1.04 at 20℃ |
| CAS Datenbank | 328-42-7(CAS DataBase Reference) |
| NIST chemische Informationen | Oxalacetic acid(328-42-7) |
| EPA chemische Informationen | Oxalacetic acetic (328-42-7) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH314 (88.5%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]P260, P264, P264+P265, P280, P301+P330+P331, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P321, P337+P317, P363, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 61 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Chemical: Butanedioic acid, oxo-Status: Active Update: 14-04-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/22927Butanedioic acid, oxo-: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | Evaluation - Chemicals that are unlikely to require further regulation to manage risks to environment |
| Gefahrenübersicht | Causes convulsions in acute intraperitoneal studies of mice[RTECS] Causes burnsInhalation may cause corrosive injuries to upper respiratory tract and lungs[Alfa Aesar MSDS] See Oxalic acid and Acetic acid. |
| Hazard Classes and Categories | Skin Corr. 1B (88.5%) |
| Unerwünschte Wirkungen | Dermatotoxin - Skin burns. |
| Wassergefährdungsklasse (WGK) | 3 |
| TSCA-Inventar-Status | TSCA listed |
| UN-Transportnummer | UN 3261 8/PG 2 |
| Zollcode | 29183000 |
| R-Sätze (R) | 34 |
| Gefahrensymbole | C |
| Sicherheitshinweise (S) | 26-36/37/39-45 |
| Gefahrenklasse | 8Eye Irrit. 2 |
| Verpackungsgruppe | II |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Beschreibung
Oxaloacetic acid, also known as oxalacetic acid, is is an α-keto acid and a key component of cellular metabolism in its conjugate base form, oxaloacetate. Oxaloacetate reacts with acetyl-coenzyme A (acetyl-CoA; ) and water to form citrate in the first step of the citric acid cycle and is regenerated by oxidation of L-malate in the final step. It is an intermediate in gluconeogenesis that is formed in mitochondria via carboxylation of pyruvate and subsequently decarboxylated and phosphorylated to form phosphoenolpyruvate. It can be converted to aspartate via addition of an amino group from glutamate. Oxaloacetate (30 μmol/min per 100 g for 30 minutes, i.v.) reduces blood glutamate levels, severity of neurological dysfunction, and brain edema in a rat model of closed head injury.
Verwenden
Oxaloacetic acid is a substrate for malate dehydrogenase and oxaloacetate decarboxylase. It is an inhibitor of succinic dehydrogenase. It is four carbon dicarboxylic acid that is an intermediate in the citric acid cycle and glucogenesis.